Table 1 Patient characteristics
All patients (n = 40) | |
 Age, year | 56.9 ± 10.8 |
 Male gender, n (%) | 28 (70.0%) |
 Tumor type, n (%) | |
  Colon | 20 (50.0%) |
  Hepatocellular carcinoma | 7 (17.5%) |
  Pancreas Ca | 6 (15.0%) |
  Others* | 7 (17.5%) |
 Lung shunt fraction, % (1st treatment) | 6.7 ± 2.6 |
  Lung shunt fraction with 5–10%, n (%) | 26 (65%) |
  Lung shunt fraction with 10–15%, n (%) | 6 (15%) |
  Lung shunt fraction with 15–20%, n (%) | 0 (0%) |
 Treatment radiation dose, GBq (1st treatment) | 1.6 ± 0.3 |
 Lung exposure dose, Gy (1st treatment) | 6.7 ± 2.8 |
Patients receiving two treatments (n = 11) | |
 Age, year | 58.5 ± 11.0 |
 Male gender, n (%) | 7 (63.6%) |
 Tumor type, n (%) |  |
  Colon | 6 (54.5%) |
  Hepatocellular carcinoma | 2 (18.2%) |
  Pancreas Ca | 1 (9.1%) |
  Others†| 2 (18.2%) |
 Lung shunt fraction, % (2nd treatment) | 7.5 ± 3.0 |
  Lung shunt fraction with 5–10%, n (%) | 6 (55%) |
  Lung shunt fraction with 10–15%, n (%) | 1 (9%) |
  Lung shunt fraction with 15–20%, n (%) | 2 (18%) |
 Treatment radiation dose, GBq (2nd treatment) | 1.6 ± 0.2 |
 Lung exposure dose, Gy (2nd treatment) | 7.7 ± 3.0 |